Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

  • This share is currently suspended. It was suspended at a price of 6.75
  • There is currently no data for DCTA

G+ textiles certified as 'non-irritating'

14 Nov 2017 07:00

RNS Number : 3829W
Directa Plus PLC
14 November 2017
 

14 November 2017

 

Directa Plus plc

("Directa Plus" or the "Company")

 

Graphene Plus textiles certified as 'non-irritating' for human skin

 

Directa Plus plc (AIM: DCTA), a producer and supplier of graphene-based products for use in consumer and industrial markets, is pleased to announce that its Graphene Plus (G+) membrane and G+ printed fabrics have received international certification from Complife Italia Srl (formerly 'Farcoderm Srl') ("Complife"), the independent toxicity testing organisation, confirming that they do not cause any irritation to human skin.

 

Complife is a specialist testing agency that assesses safety, tolerability and sensory aspects of all products that may come in contact with human skin. The Company's G+ membrane and printed fabrics were dermatologically tested by Complife, involving 48-hour patch tests on 25 individuals, and certified as 'non-irritating'. This complements previous tests conducted by Complife (then operating as Farcoderm) on all of Directa Plus' graphene-based materials, which were certified as safe for human contact.

 

Giulio Cesareo, Chief Executive Officer of Directa Plus, said: "We are pleased to have our G+ membrane and printed fabrics proven to be non-irritating to human skin. This adds to the certification we received last year that our graphene-based materials are non-toxic and non-cytotoxic. With our Graphene Plus textiles, our customers can truly differentiate their products as innovative, performance-enhancing and comfortable to wear. We have always prided ourselves on the safety and environmental credentials of our production processes and graphene-based products, and this new certification further represents that commitment."

 

 

Enquiries

 

Directa Plus plc

Giulio Cesareo, CEO

Marco Ferrari, CFO

+39 02 36714458

Luther Pendragon (Financial PR)

Harry Chathli, Claire Norbury, Alexis Gore

+44 20 7618 9100

 

 

About Directa Plus

 

Directa Plus is one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets worldwide. By incorporating Directa Plus' unique graphene blends, identified by the G+ brand, its customers can enhance the performance of their end products without significantly increasing their cost. Directa Plus graphene-based products are natural, chemical-free, sustainably produced and tailored to specific customer requirements for commercial applications such as smart textiles, tyres, composite materials and environmental solutions.

 

Established in 2005, the Company has a patented technology process and a scalable and exportable manufacturing model. It produces graphene-based products at its own factory in Lomazzo, Italy, and can set up additional production at customer locations to reduce transport costs, waste and time-to-utilisation. Directa Plus partners with customers to enable them to offer the high-performance benefits of graphene in their own products.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFMMMMZFMGNZZ
Date   Source Headline
28th May 20267:00 amRNSCancellation - Directa Plus plc
27th Apr 20266:00 pmRNSDirecta Plus
27th Apr 20263:21 pmRNSAppointment of Administrators
14th Apr 20267:00 amRNSUpdate on Funding
13th Apr 20267:43 amRNSUpdate on Further Funding
13th Apr 20267:42 amRNSSuspension - Directa Plus PLC
30th Mar 20267:00 amRNSUpdate on Funding
20th Mar 20267:00 amRNSAIM Rule 17 and Schedule 2(g) update
27th Feb 20267:00 amRNSUpdate on Funding and Board change
7th Jan 20267:00 amRNSFull year trading and operational update
15th Dec 20253:26 pmRNSGrant of 2025 LTIP Awards
24th Sep 20257:00 amRNSHalf Year Report
17th Sep 20257:00 amRNSNotice of interim results presentations
4th Aug 202511:26 amRNSPDMR Dealing
4th Aug 20257:00 amRNSHalf Year Trading Update and Notice of Results
30th Jun 20255:03 pmRNSResult of AGM
19th Jun 20257:00 amRNSDirector/PDMR Shareholding
17th Jun 20257:00 amRNSDirector/PDMR Shareholding
16th Jun 20253:27 pmRNSDirector/PDMR Shareholding
16th Jun 202511:34 amRNSDirector/PDMR Shareholding
10th Jun 20257:00 amRNSNotice of Investor Presentation
6th Jun 20257:00 amRNSPosting of Annual Report and Notice of AGM
3rd Jun 20257:00 amRNSFinal Results
28th May 20257:00 amRNSNotice of Results
14th Apr 20257:00 amRNSContract Win
7th Apr 20257:00 amRNSTrading and Operational Update & Notice of Results
10th Feb 20257:00 amRNSSetcar secures a new contract win and a renewal
19th Nov 20247:00 amRNSAppointment of Nominated Adviser and Broker
25th Sep 20247:00 amRNSHalf-year Report
13th Sep 20247:00 amRNSNotice of Results
26th Jul 20244:33 pmRNSResult of General Meeting
4th Jul 20242:24 pmRNSNotification of major holdings
2nd Jul 20244:23 pmRNSNotification of major holdings
1st Jul 20243:16 pmRNSNotification of major holdings
28th Jun 20243:09 pmRNSDirectors’ Participation in Fundraising
28th Jun 20242:57 pmRNSHolding(s) in Company
28th Jun 202412:09 pmRNSPosting of Annual Report & Accounts
27th Jun 20243:50 pmRNSResult of AGM & GM
26th Jun 20247:00 amRNSFinal Results
24th Jun 20247:00 amRNSUpdate on Voting & Action to be Taken
12th Jun 20241:06 pmRNSPosting of Circular and Notice of General Meeting
11th Jun 202410:40 amRNSResult of Placing and Subscription
11th Jun 20247:00 amRNSProposed equity raise
3rd Jun 20247:00 amRNSNotice of AGM
29th May 20247:00 amRNSGipave selected for Rome 2025 Jubilee project
15th Apr 20243:01 pmRNSNotification of major holdings
12th Apr 20247:00 amRNSGiPave® installed at Imola Circuit
25th Mar 20247:00 amRNSEUR 1,000,000 Loan Agreement Signed
22nd Mar 20247:00 amRNSCollaboration with UK-based Heathcoat Fabrics
26th Feb 20247:00 amRNSAcquisition of 49% minority interest in Setcar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.